Monte Rosa Therapeutics, Inc. 4

COO Jennifer Champoux exercised 4,351 options at $3.98 and sold 4,351 Monte Rosa Therapeutics (GLUE) common shares at a $23.38 weighted average price under a Rule 10b5-1 plan.

On July 15, 2026, Monte Rosa Therapeutics, Inc. Chief Operating Officer Jennifer Champoux exercised 4,351 stock options at $3.98 per share and received an equivalent 4,351 shares of common stock, then immediately sold those 4,351 shares at a weighted average price of $23.3808 per share under a Rule 10b5-1 trading plan, realizing an implied gross transaction value of roughly $101,800 on the sale versus an exercise cost of about $17,300. Following these transactions, her directly held common stock position decreased from 66,722 shares to 62,371 shares, with an estimated post-transaction holding value of approximately $1.46 million based on the reported sale price as a proxy for market price; the option exercise reflects scheduled vesting of a long-term equity award rather than a discretionary open-market purchase.

Filing Facts

CIK

1826457

Ticker

GLUE

Form

4

Source Type

fda

Accession

0001193125-26-306110

Alert Tier

5